Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: Validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice

Circulation

Volumn 125, Issue 25, 2012, Pages 3117-3126

  Wang, Xiaowei ^a,b   Hagemeyer, Christoph E ^a,b   Hohmann, Jan David ^a   Leitner, Ephraem ^a   Armstrong, Paul C ^a   Jia, Fu ^a   Olschewski, Manfred ^c   Needles, Andrew ^d   Peter, Karlheinz ^a,b   Ahrens, Ingo ^a,e  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF FREIBURG   (Germany)

^d VisualSonics   (Canada)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

antibodies; microbubbles; molecular imaging; platelets; thrombolysis; thrombosis; ultrasonography

Indexed keywords

FERRIC CHLORIDE; FIBRINOGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MICROBUBBLE; MICROTHROMBUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; ULTRASOUND;

ANIMALS; BINDING SITES, ANTIBODY; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INTEGRIN BETA3; MICE; MICE, INBRED C57BL; MICROBUBBLES; MOLECULAR IMAGING; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEIN IIB; SINGLE-CHAIN ANTIBODIES; THROMBOLYTIC THERAPY; THROMBOSIS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84863223801     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.030312     Document Type: Article

References (48)

1. Huo Y, Schober A, Forlow S, Smith D, Hyman M, Jung S, Littman D, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2002;9:61-67.
2. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143. (Pubitemid 34212626)
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918.
4. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Eng J Med. 2005;352:1685-1695.
5. Rader D, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-913. (Pubitemid 351301745)
6. Gawaz M, Langer H, May A. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378-3384. (Pubitemid 43121822)
7. Lindemann S, Krämer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007;5:203-211. (Pubitemid 46958835)
8. Madan M, Berkowitz S, Tcheng J. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998;98:2629-2635. (Pubitemid 29001205)
9. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen Y, Hagemeyer C, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K. Conformation-specific blockade of the integrin GP IIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25-33. (Pubitemid 44297052)
10. Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Buttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004;18:1704-1706. (Pubitemid 39561657)
11. Stoll P, Bassler N, Hagemeyer C, Eisenhardt S, Chih C, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K. Targeting ligand-induced binding sites on GP IIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol. 2007;27:1206-1212. (Pubitemid 46641980)
12. von zur Muhlen C, Peter K, Ali Z, Schneider J, McAteer M, Neubauer S, Channon K, Bode C, Choudhury R. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res. 2008;46:6-14.
13. von zur Muhlen C, Sibson N, Peter K, Campbell S, Wilainam P, Grau G, Bode C, Choudhury R, Anthony D. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest. 2008;118:1198-1207.
14. von zur Muhlen C, von Elverfeldt D, Choudhury R, Ender J, Ahrens I, Schwarz M, Hennig J, Bode C, Peter K. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging. 2008;7:59-67.
15. von zur Muhlen C, von Elverfeldt D, Moeller J, Choudhury R, Paul D, Hagemeyer C, Olschewski M, Becker A, Neudorfer I, Bassler N, Schwarz M, Bode C, Peter K. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118:258-267.
16. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res. 2011;108:593-606.
17. Pochon S, Tardy I, Bussat P, Bettinger T, Brochot J, von Wronski M, Passantino L, Schneider M. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol. 2010;45:89-95.
18. Pysz M, Foygel K, Rosenberg J, Gambhir S, Schneider M, Willmann J. Antiangiogenic cancer therapy: monitoring with molecular us and a clinically translatable contrast agent (BR55). Radiology. 2010;256: 519-527.
19. Kaufmann B, Carr C, Belcik J, Xie A, Yue Q, Chadderdon S, Caplan E, Khangura J, Bullens S, Bunting S, Linder J. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol. 2010;30:54-59.
20. Kaufmann B, Sanders J, Davis C, Xie A, Aldred P, Sarembock I, Lindner J. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276-284. (Pubitemid 47196563)
21. Barreiro O, Aguilar R, Tejera E, Megas D, de Torres-Alba F, Evangelista A, Sánchez-Madrid F. Specific targeting of human inflamed endothelium and in situ vascular tissue transfection by the use of ultrasound contrast agents. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:997-1005.
22. Weller G, Lu E, Csikari M, Klibanov A, Fischer D, Wagner W, Villanueva F. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation. 2003;108:218-224. (Pubitemid 36871306)
23. Weller G, Villanueva F, Klibanov A, Wagner W. Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium. Ann Biomed Eng. 2002;30:1012-1019. (Pubitemid 35457697)
24. Kaufmann B, Lewis C, Xie A, Mirza-Mohd A, Lindner J. Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography. Eur Heart J. 2007;28:2011-2017. (Pubitemid 47591499)
25. Lindner J, Song J, Christiansen J, Klibanov A, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation. 2001;104:2107-2012.
26. Takalkar A, Klibanov A, Rychak J, Lindner J, Ley K. Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J Controlled Release. 2004;96:473-482. (Pubitemid 38553925)
27. Villanueva F, Lu E, Bowry S, Kilic S, Tom E, Wang J, Gretton J, Pacella J, Wagner W. Myocardial ischemic memory imaging with molecular echocardiography. Circulation. 2007;115:345-352. (Pubitemid 46151660)
28. McCarty O, Conley R, Shentu W, Tormoen G, Zha D, Xie A, Qi Y, Zhao Y, Carr C, Belcik T, Keene D, de Groot P, Linder J. Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:947-955.
29. Hagemeyer C, Schwarz M, Peter K. Single-chain antibodies as new antithrombotic drugs. Sem Thromb Hemost. 2007;33:185-195. (Pubitemid 46427762)
30. Alonso A, Della Martina A, Stroick M, Fatar M, Griebe M, Pochon S, Schneider M, Hennerici M, Allemann E, Meairs S. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke. 2007;38:1508-1514. (Pubitemid 46684166)
31. Schumann P, Christiansen J, Quigley R, Mccreery T, Sweitzer R, Unger E, Lindner J, Matsunaga T. Targeted-microbubble binding selectively to GP IIb IIIa receptors of platelet thrombi. Invest Radiol. 2002;37:587-593. (Pubitemid 35231692)
32. Takeuchi M, Ogunyankin K, Pandian N, McCreery T, Sweitzer R, Caldwell V, Unger E, Avelar E, Sheahan M, Connolly R. Enhanced visualization of intravascular and left atrial appendage thrombus with the use of a thrombustargeting ultrasonographic contrast agent (MRX-408A1): in vivo experimental echocardiographic studies. J Am Soc Echocardiogr. 1999;12: 1015-1021.
33. Unger E, McCreery T, Sweitzer R, Shen D, Wu G. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am J Cardiol. 1998;81: 58G-61G. (Pubitemid 28309282)
34. Ferrante E, Pickard J, Rychak J, Klibanov A, Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release. 2009;140:100-107.
35. Weller G, Villanueva F, Tom E, Wagner W. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng. 2005;92:780-788. (Pubitemid 41772473)
36. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7e3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res. 2002;107: 121-12837.
37. Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost. 1999;82:326-336.
38. Lele M, Sajid M, Wajih N, Stouffer GA. Eptifibatide and 7e3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation. 2001;104: 582-587. (Pubitemid 32738129)
39. Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kubler W, Bode C. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation. 2000;102:1490-1496.
40. Porter TR, Kricsfeld D, Cheatham S, Li S. The effect of ultrasound frame rate on perfluorocarbon-exposed sonicated dextrose albumin microbubble size and concentration when insonifying at different flow rates, transducer frequencies, and acoustic outputs. J Am Soc Echocardiogr. 1997;10: 593-601. (Pubitemid 127799944)
41. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost. 2011;9:92-99.
42. Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE, Albertoni C, Leoni B, Rosi A, D'Alessio V, Deiana K, Paganelli G, De Santis R. Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. Cancer Biother Radiopharm. 2010;25: 563-570.
43. Ta HT, Prabhu S, Leitner E, Jia F, von Elverfeldt D, Jackson K, Heidt T, Nair A, Pearce H, von zur Muhlen C, Wang X, Peter K, Hagemeyer CE. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res. 2011;109:365-373.
44. Davi G, Patrono C. Platelet activation and atherothrombosis. N Eng J Med. 2007;357:2482-2494.
45. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887-896.
46. Ruggeri Z. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234. (Pubitemid 35373553)
47. Weyrich A, Cipollone F, Mezzetti A, Zimmerman G. Platelets in atherothrombosis: new and evolving roles. Curr Pharm Design. 2007;13: 1685-1691. (Pubitemid 46979722)
48. Kramer MCA, Rittersma SZH, de Winter RJ, Ladich ER, Fowler DR, Liang YH, Kutys R, Carter-Monroe N, Kolodgie FD, van der Wal AC, Virmani R. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Col Cardiol. 2010;55:122-132.